Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Teicoplanin for Staphylococcus aureus Infections in Cystic Fibrosis
2024-517820-21-00Phase 2Authorised
- Sponsor
- Azienda Ospedaliera Universitaria Integrata Verona
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of teicoplanin in cystic fibrosis (CF), sponsored by Azienda Ospedaliera Universitaria Integrata Verona. Primary endpoint: Safety and tolerability of inhaled teicoplanin. Planned start Oct 2024; status: authorised.
02
Drugs
teicoplanin
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2024-517820-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517820-21-00.